These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16271514)

  • 1. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 4. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 7. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 10. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse drug effects: new information about an old problem.
    Miller CA
    Geriatr Nurs; 2001; 22(6):336-7. PubMed ID: 11780009
    [No Abstract]   [Full Text] [Related]  

  • 12. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 13. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 14. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
    Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 16. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 17. MedWatch: the FDA medical products reporting program.
    Rheinstein PH
    Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MedWatch targets reporting of serious adverse events.
    VanAmringe M
    Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
    [No Abstract]   [Full Text] [Related]  

  • 20. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.